Short answer
MeiraGTx Holdings plc (MGTX) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $410,000 (down 96.2% year over year) with net income of −$51M.
Q3 2025 key financials · XBRL
- Revenue
- $410,000
- −96.2% YoY · −92.7% QoQ
- Net income
- −$51M
- −28.4% YoY · −30.2% QoQ
- Operating margin
- -11232.0%
- EPS (diluted)
- −$0.62
- −14.8% YoY · −29.2% QoQ
Source: XBRL data from the MeiraGTx Holdings plc (MGTX) Q3 2025 10-Q on SEC EDGAR. USD.
MeiraGTx Holdings plc Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net loss $50.5M vs $39.3M YoY; operating expenses $46.5M vs $51.0M
- Cash, equivalents and restricted cash $17.1M at September 30, 2025; $2.8M receivables from Johnson & Johnson
- Hologen payments $28.0M during nine months, plus $22.0M received in fourth quarter 2025
- Funding expected to support operations into second half of 2027; AAV-GAD Phase 3 initiation targeted in coming months
Risk Factors
- Newly added acquisition risk triggered by July 2025 Smart Immune asset purchase, with integration potentially disrupting operations
- Financing dilution risk: ATM program raised $9.9 million from 1,510,300 shares during nine months ended September 30, 2025
- Regulatory compliance risk: SEC climate-disclosure rules stayed pending litigation, creating evolving ESG obligations
- Currency risk: unhedged fluctuations between the U.S. dollar, pound sterling, and euro may affect results and cash flows
- Ownership concentration risk: insiders and shareholders owning over 5% collectively control approximately 55.1% of ordinary shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MeiraGTx Holdings plc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.